ENDRA Life Sciences Inc. (NDRA)
After hours:
| Previous Close | 0.3126 |
| Open | 0.3100 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2811 - 0.3171 |
| 52 Week Range | 0.2210 - 2.7900 |
| Volume | |
| Avg. Volume | 187,751 |
| Market Cap | 3.068M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
ENDRA Provides Update Following In-person Meeting with FDA
ANN ARBOR, Mich., May 20, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced that it has completed what it considers to be a highly informative pre-submission meeting with the U.S. Food and Drug Administration (FDA) related to the clinical trial design of the TAEUS liver device in support of its U.S. De Novo filing.
- Business Wire
ENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business Update
ANN ARBOR, Mich., May 14, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2024 and provided a business update.
- Business Wire
ENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024
ANN ARBOR, Mich., May 07, 2024--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months ended March 31, 2024 on Tuesday, May 14, 2024 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer
